CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...

Eli Lilly ( LLY 2.92%) and Novo Nordisk ( NVO -0.89%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

"If approved, the company ... at Weill Cornell Medicine, calls the new drug "transformational." Aronne has been treating obesity for 35 years and is a consultant for Eli Lilly.

Big move on Thursday as investors in Eli Lilly and Company (LLY) endured an almost 12% downside as investors consider the aftermath of the CVS formulary decision changes that impacted the ...

Indianapolis-based pharmaceutical giant Eli Lilly and Company plans to build four new manufacturing facilities across the country. On an investment spree with billions of dollars’ worth of ...

The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE:LLY) and its position in the obesity and adjacent markets. The main competitor Novo Nordisk A/S (NVO ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (NYSE: LLY). It is the most valuable healthcare company in the world, with a market ...

Eli Lilly CEO Dave Ricks ... have on American exporters like Eli Lilly. In an earnings call May 1, Ricks said leaders of the Indianapolis pharmaceutical company support the government's goals ...